While only indirectly supporting attenuation of fibrogenic activity, both semaglutide and lanifibranor significantly lowered α-SMA levels, Similar distinct histological benefits of semaglutide and lanifibranor monotherapy have recently been reported in GAN DIO-NASH mice without HCC (treatment start after 34–38 weeks of GAN diet feeding, fibrosis stage F1-F3)20, which is in close agreement with primary endpoint outcomes in corresponding clinical trials in NASH patients with fibrosis (stage F1-F3)25,26. The gene discussed is ACTA1; the disease is fibrosis.